Biodesix Closes Series D Financing
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
The new capital will support commercialization activities for the Company’s first product VeriStrat®, a blood-based test that helps physicians guide treatment for patients with non-small cell lung cancer (NSCLC). Funding will also support clinical validation studies, product development, and ongoing collaborations with a number of biotechnology and pharmaceutical companies.
